Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524558 | NSE Symbol : NEULANDLAB | ISIN : INE794A01010 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
23-Jan-2025	10-Feb-2025	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve The Unaudited Financial Results of the Company For The Quarter And Nine Months Ended December 31 2024 Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2024 (As Per BSE Announcement Dated on 10/02/2025)
17-Oct-2024	06-Nov-2024	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024 Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024 (As Per BSE Announcement Dated on 06.11.2024)
17-Jul-2024	01-Aug-2024	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve the unaudited financial results of the Company for the Quarter ended June 30 2024 Unaudited Financial results for quarter ended June 30, 2024 (As per BSE Announcement Dated on 01/08/2024)
23-Apr-2024	10-May-2024	Accounts	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2024 and; to recommend final dividend if any for the financial year ended March 31 2024 Recommendation of final dividend for the financial year 2023-24 Audited Financial Results and recommendation of final dividend for financial year 2023-2024 Recommendation of final dividend for the financial year 2023-24 Book closure for dividend and Annual General Meeting scheduled on Wednesday, July 31, 2024 Re-appointment of Statutory Auditors (As Per BSE Announcement dated on 10.05.2024)
25-Jan-2024	08-Feb-2024	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve The Unaudited Financial Results of the Company For The Quarter And Nine Months Ended December 31 2023 Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023 (As Per BSE Announcement dated on 08.02.2024)
25-Jan-2024	25-Jan-2024	Others	Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
10-Nov-2023	10-Nov-2023	Others	Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
11-Oct-2023	07-Nov-2023	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve The Unaudited Financial Results of the Company For The Quarter And Half Year Ended September 30 2023 unaudited financial results of the Company for the quarter and half year ended September 30, 2023 unaudited financial results of the Company for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 07.11.2023)
10-Jul-2023	03-Aug-2023	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 inter alia to consider and approve the unaudited financial results of the Company for the Quarter ended June 30 2023 Unaudited Financial results for quarter ended June 30, 2023 (As Per BSE Announcement dated on 03.08.2023)
27-Jun-2023	27-Jun-2023	AGM	Change in Directorate
14-Apr-2023	11-May-2023	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 ,inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2023, and; to recommend final dividend, if any, for the financial year ended March 31, 2023 Outcome of Board Meeting held on May 11, 2023 - Audited Financial Results and recommendation of Final Dividend for financial year 2022-2023 Recommendation of final dividend for the financial year 2022-23. The Board of Directors of the Company at its meeting held on May 11, 2023, has inter alia approved the following: 1. Re-appointment of Mr. Davuluri Sucheth Rao (DIN: 00108880) as Whole Time Director of the Company designated as Vice Chairman & CEO, for a further period of 5 (five) years, w.e.f. August 1, 2023, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. 2. Re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737) as Whole Time Director of the Company designated as Executive Chairman, for a further period of 5 (five) years, w.e.f. April 1, 2024, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. Machine-readable version / legible copy of the financial results for the quarter and year ended March 31, 2023 (As Per BSE Announcement Dated on 11/05/2023) The Board of Directors of the Company at their meeting held on May 12, 2023 (today) have, inter alia; a. approved the appointment of Dr. Brinda Jagirdar, as an Additional Director (in the category of Non-Executive and Independent Director), effective May 12, 2023. b. taken on record the retirement of Dr Sheela Bhide, Non Executive - Independent Director, in accordance with policy of the Company effective closure of business hours on May 12, 2023. The Board while acknowledging her significant contributions to its discussions and decisions on various strategic and governance matters, appreciated her valuable advice and guidance rendered during her tenure as an Independent Director. Pursuant to the aforesaid changes the Board Composition of the Board of Directors continues to be in compliance with Regulation 17 of SEBI LODR. The details pursuant to Regulation 30 of SEBI LODR are enclosed as Annexure. (As Per BSE Announcement Dated on 12.05.2023)
20-Jan-2023	13-Feb-2023	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2022 Unaudited Financial Results for the quarter and nine months ended December 31, 2022, Along With The Press Release And Investor Presentation. In line with Neuland's commitment to sustainable development and environmental, social and governance (ESG) priorities, the Company has been taking various initiatives to accelerate its ESG journey. With a view to further strengthen its commitment and enhance Board's oversight on sustainability and ESG matters, the Board of Directors at its meeting held on February 13, 2023 has expanded the scope of the Risk Management Committee and included sustainability and ESG related matters under its purview and renamed the Committee as Risk & Sustainability Committee. (As Per BSE Announcement dated on 13.02.2023)
23-Nov-2022	23-Nov-2022	Change in Other Executives	Appointment of Mr. Abhijit Majumdar, as the Chief Financial Officer (CFO) and KMP of the Company.
14-Oct-2022	10-Nov-2022	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2022 Unaudited Financial Results For The quarter and half year ended September 30, 2022 Unaudited Financial Results for the quarter and half year, Along With The Press Release And Investor Presentation. Unaudited Financial Results for the quarter and half year quarter and half year ended September 30, 2022, Along With The Press Release And Investor Presentation. (As per BSE Announcement Dated on 10/11/2022)
11-Jul-2022	03-Aug-2022	Quarterly Results	NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2022 inter alia to consider and approve the unaudited financial results of the Company for the Quarter ended June 30 2022 Unaudited Financial Results For The Quarter Ended June 30, 2022, along with the Press Release and Investor Presentation. (As Per BSE Announcement dated on 03.08.2022)

1 2

LOGIN HERE

Neuland Laboratories Ltd

Board Meeting